Daily as of 3 Nov 16:00 ET
- Price
- above both $164.85 vs 50 $146.72 / 200 $147.60
- Projection
- 🟨Golden cross projected in 13 bars
- Test
- Active cross test, 2 bars at the 50, 2 bars left
- Last cross
- 💀Death cross 27 Oct 2026 · projected 16 bars out
NBIX | Neurocrine BiosciencesNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history
$164.85
+$19.50 (+13.42%)
Neurocrine Biosciences (NBIX) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2018.
Right now the daily is the chart to watch. NBIX printed a death cross in Oct 2026, and price has already pulled back to the 50 inside the seven-bar window, so the cross test is open. On both the daily and the 4-hour, price sits above the 50 and the 200; on the weekly it is between the two.
Timeframe summary
Weekly as of 30 Oct 16:00 ET
- Price
- between the two $146.10 vs 50 $146.74 / 200 $128.36
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross week of 12 Dec 2022 · projected 20 bars out
4-hour as of 3 Nov 16:00 ET
- Price
- above both $164.85 vs 50 $142.99 / 200 $156.76
- Projection
- 🟨Golden cross estimated in 20 to 29 bars
- Test
- No active test
- Last cross
- 💀Death cross 3 Sep 2026 bar 2 · projected 29 bars out · tested 4 bars
Cross history
| Crossed | Direction | Timeframe | Projected | Cross test |
|---|---|---|---|---|
| 27 Oct 2026 | 💀Death steep | daily | 16 bars out | Active Cross Test |
| 3 Sep 2026 | 💀Death | 4-hour | 29 bars out | 4 bar cross test |
| 2 Jun 2026 | 🟨Golden steep | daily | 29 bars out | Not tested |
| 12 May 2026 | 🟨Golden | 4-hour | 14 bars out | Not tested |
| 2 Mar 2026 | 💀Death steep | daily | 11 bars out | Not tested |
About NBIX
ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$172M
4-hour coverageYes, since Oct 2025
History on recordSince 2018
SectorHealthcare
Cap bandlarge